FDA 483 - Novo Nordisk A/S - May 04, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Novo Nordisk A/S in Kalundborg, Denmark, revealed significant deficiencies in contamination control, investigation of discrepancies, and complaint handling. The firm experienced multiple mold and bacterial recoveries in manufacturing areas, coupled with inadequate environmental monitoring and disinfection procedures. Additionally, investigations into product deviations and customer complaints were found to be insufficient, indicating a need for improved quality control and robust procedural adherence.
ID · c88acfb5-d361-4369-8bff-87d2b9102820